Capricor shares rise before FDA decision as investors read launch hiring as a signal
Capricor shares rose over 4% overnight as retail investors read launch hiring as a sign FDA approval for Deramiocel may be near, per Stocktwits.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Shares of Capricor Therapeutics (CAPR) climbed more than 4% in overnight trading late Sunday. Retail investors saw open positions on the company's careers page, including senior director roles in commercial operations and analytics and in patient services, as possible hints that FDA approval could be close, Stocktwits reported.
The stock had snapped a three-week losing streak with an 8% gain last week, though it fell 33% in October. The FDA moved its decision deadline for the Duchenne muscular dystrophy therapy Deramiocel from August 22 to November 22 after receiving more trial data. As of June 30, the company reported $237.9 million in cash, equivalents and investments.
why it matters
The timing and scale of the launch depend on the regulator's verdict, which is why investors are parsing staffing moves closely. CAPR is down 78% year to date, so the stock remains highly sensitive to any news about the review.
tags
instruments
sources
- CAPR Stock Rallies Into FDA Decision Month: Retail Spots Approval ‘Tea Leaves’ In Capricor’s Launch Team Hiring — Stocktwits, 2 November 2026 at 04:21 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗